Proactive Investors - Run By Investors For Investors

CannPal Animal Therapeutics delivers a medical cannabis milestone

CannPal is researching the benefits of medical cannabis for companion animals.
CannPal Animal Therapeutics delivers a medical cannabis milestone
CannPal is the only ASX-listed pure animal health company

CannPal Animal Therapeutics Limited (ASX:CP1) has achieved a milestone in entering into a manufacturing agreement with New Zealand based veterinary contract manufacturing organisation, Jaychem Industries Ltd.

The agreement will allow CannPal to proceed with developing DermaCann, a high-quality cannabinoid derived therapeutic that is targeted to meet GMP (Good Manufacturing Processes) standards.

The company has now commissioned pharmaceutical quality assurance and GMP compliance consultants, Seer Pharma, to perform a GMP Inspection of Jaychem to relevant standards that will apply to Dermacann in the company’s target regions.

CannPal is researching and developing medicines derived from cannabinoids to provide veterinarians with clinically validated and standardised therapeutics to treat animals in a safe and ethical way.

The core strategy is to use compounds derived from cannabis that have been de-risked in clinical humans studies, to progress straight into animal clinical trials.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full CP1 profile View Profile

CannPal Animal Therapeutics Ltd Timeline

Related Articles

A visual representation of a drug candidate working in a dog
January 29 2019
The company has reaffirmed its upcoming milestones as it confirmed December quarter achievements.
FSD Pharma facility
June 11 2019
The indoor hydroponic facility will be optimized for large-scale, medical-grade cannabis production and once complete, is expected to have over 3.9 million sq/ft available for production
cannabis leaf next to bottle
April 29 2019
The cannabis holding company has four unique, synergistic business under its umbrella

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use